Entinostat (MS-275)

For research use only.

Catalog No.S1053 Synonyms: SNDX-275

282 publications

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 57 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Entinostat (MS-275) has been cited by 282 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NFjpPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLOTWM2OD1yLkC2NUDPxE1? NH36[2tUSU6JRWK=
ALL-PO NGG5OJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT5c5dtUUN3ME2wMlA3OzV3IN88US=> MmjlV2FPT0WU
697 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7wR|dnUUN3ME2wMlA6QTd4IN88US=> NGfjO49USU6JRWK=
NCI-H748 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMUCzN|Qh|ryP NY\PRoZtW0GQR1XS
NKM-1 M3r0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMUC5NVIh|ryP NXTPbXNYW0GQR1XS
ES1 MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYru[4lPUUN3ME2wMlEyOjV3IN88US=> NGCxcnNUSU6JRWK=
NCI-H1963 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMUG1O|kh|ryP NWPHXopPW0GQR1XS
NCI-H1417 NV3xPFNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;xTWM2OD1yLkGyPVc1KM7:TR?= NE\jS3ZUSU6JRWK=
NEC8 NUS3R5hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jpT2lEPTB;MD6xN|UzPyEQvF2= NX[3[2ZiW0GQR1XS
CRO-AP2 M{H1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPlPFF6UUN3ME2wMlE3QDh7IN88US=> MXXTRW5ITVJ?
A3-KAW MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nmbmlEPTB;MD6xO|YzPyEQvF2= MX3TRW5ITVJ?
SF539 M1HPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXE[FhKSzVyPUCuNVk2QTNizszN NH;sbGFUSU6JRWK=
NOS-1 M{jNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPUPGFKSzVyPUCuNVk3OTlizszN NHXXeVhUSU6JRWK=
NTERA-S-cl-D1 M4L6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMkCxNVMh|ryP MUTTRW5ITVJ?
COR-L88 MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjKcXRXUUN3ME2wMlIzQTV7IN88US=> Mn3LV2FPT0WU
EM-2 NVTRSIVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPQUlJXUUN3ME2wMlI1ODd7IN88US=> M1v0PXNCVkeHUh?=
KARPAS-45 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfYSnJKUUN3ME2wMlI4QDN|IN88US=> MXzTRW5ITVJ?
DSH1 NI\KR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMki3NFgh|ryP NVfpR3JWW0GQR1XS
HT-144 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPpcVhKSzVyPUCuN|AzPTZizszN M2fYT3NCVkeHUh?=
ATN-1 NVfIcZZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTnTWM2OD1yLkOwOVc3KM7:TR?= MVHTRW5ITVJ?
HEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwM{GzOFgh|ryP NWjmb3AyW0GQR1XS
NB12 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m5UmlEPTB;MD6zNVc2PiEQvF2= M3npXXNCVkeHUh?=
LU-139 NHzyS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrZS|lKSzVyPUCuN|M2OSEQvF2= MoDqV2FPT0WU
J-RT3-T3-5 NH\ZcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHoNIVKUUN3ME2wMlM{PzF4IN88US=> MoDCV2FPT0WU
MOLT-13 M3X1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ewSWlEPTB;MD6zN|gyKM7:TR?= NGjt[4ZUSU6JRWK=
SR NF20fHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLxdWxKSzVyPUCuN|QzPjFizszN M1T4bnNCVkeHUh?=
CMK MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\4bXpPUUN3ME2wMlM2PzJ5IN88US=> NYHGTohsW0GQR1XS
ES8 NHjROIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3DNYN1UUN3ME2wMlM3ODJ{IN88US=> MnjCV2FPT0WU
LB647-SCLC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\HTWM2OD1yLkO2O|Mh|ryP NXvjV|BFW0GQR1XS
TE-8 NGjtW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37HNGlEPTB;MD6zOlk{PSEQvF2= NHTkR2NUSU6JRWK=
BV-173 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwM{exNlEh|ryP M{\sfHNCVkeHUh?=
DEL MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPJVYpVUUN3ME2wMlM4PDh5IN88US=> NEe2Xo9USU6JRWK=
ARH-77 M1HHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TGWGlEPTB;MD6zPFE6OyEQvF2= Mlq1V2FPT0WU
NCCIT NWm2NIlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfveZhsUUN3ME2wMlM5PjR7IN88US=> M3ftbnNCVkeHUh?=
RPMI-8402 NUfxbJU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS1TJR{UUN3ME2wMlM5PzBzIN88US=> M3vlOnNCVkeHUh?=
MONO-MAC-6 Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXqTWM2OD1yLkO4O|c3KM7:TR?= NYjqSodxW0GQR1XS
SK-MM-2 MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrhUIN1UUN3ME2wMlM6QDZ6IN88US=> NIr0NI1USU6JRWK=
CHP-126 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwNECyN|Eh|ryP Mof3V2FPT0WU
A101D MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwNECzJO69VQ>? NVXXT|RIW0GQR1XS
SCH NE\XTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj6VlhXUUN3ME2wMlQxOzR{IN88US=> MWrTRW5ITVJ?
NMC-G1 M1q5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXFToxKSzVyPUCuOFA{PjdizszN NY\4d2NvW0GQR1XS
NCI-H209 MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDYV4RKSzVyPUCuOFA3OTNizszN MkjVV2FPT0WU
MOLT-16 NYfyVGRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jsTGlEPTB;MD60NVAyPyEQvF2= MUTTRW5ITVJ?
RPMI-6666 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WzXWlEPTB;MD60NVEzKM7:TR?= Mme2V2FPT0WU
OPM-2 M4jvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu0S|N2UUN3ME2wMlQyPTF|IN88US=> NWe5U2RPW0GQR1XS
MRK-nu-1 M{HUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwNEOxOVMh|ryP NWnKb41sW0GQR1XS
BC-1 NFvlZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TpbWlEPTB;MD60N|QxOyEQvF2= NETzdmpUSU6JRWK=
MHH-NB-11 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm0dJpXUUN3ME2wMlQ{PDV|IN88US=> MU\TRW5ITVJ?
Ramos-2G6-4C10 MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK2eVl5UUN3ME2wMlQ{QDl5IN88US=> NHn1SGhUSU6JRWK=
LS-513 M2DKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnnTWM2OD1yLkS0OVAyKM7:TR?= M2nqS3NCVkeHUh?=
K5 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVywR|hSUUN3ME2wMlQ4ODJ3IN88US=> NVrZdGRHW0GQR1XS
HOP-62 NGXHZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrDb2dOUUN3ME2wMlQ5OzV6IN88US=> NI\yNWNUSU6JRWK=
NCI-H187 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j3WWlEPTB;MD60PVIzPyEQvF2= NV3sSmJxW0GQR1XS
BE-13 Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfMTWM2OD1yLkS5OlYyKM7:TR?= MmH0V2FPT0WU
HC-1 M3zYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O2SGlEPTB;MD61NFQ4OyEQvF2= MnPkV2FPT0WU
ACN M2PPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\x[5BQUUN3ME2wMlUyODJ6IN88US=> Mn7lV2FPT0WU
HCC1599 NWnrS2tyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTDbIxOUUN3ME2wMlUyPTdizszN NUHqcGJ7W0GQR1XS
MV-4-11 M3fJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHqcnluUUN3ME2wMlU{ODRzIN88US=> MUnTRW5ITVJ?
LC-2-ad M2LHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjVblFWUUN3ME2wMlU{PjZ|IN88US=> Mn;vV2FPT0WU
HL-60 NWXncolvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwNUSyOlEh|ryP MWTTRW5ITVJ?
NB17 M1TL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwNUSzPEDPxE1? NYnMWXlnW0GQR1XS
TE-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPNTWM2OD1yLkW1N|A3KM7:TR?= M4X0UXNCVkeHUh?=
NCI-H524 MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnoPFNvUUN3ME2wMlU2PDBzIN88US=> M3OwUHNCVkeHUh?=
MZ7-mel NIezWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfXXGVKSzVyPUCuOVYyODVizszN NX35WW9WW0GQR1XS
L-363 NWD0NVk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13BR2lEPTB;MD61OlY2PyEQvF2= MonEV2FPT0WU
BL-41 NVXmW2RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzoPFM6UUN3ME2wMlU3QDh7IN88US=> MkfZV2FPT0WU
LU-134-A MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\xeoljUUN3ME2wMlU4ODd|IN88US=> MlvZV2FPT0WU
SIG-M5 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvsTWM2OD1yLkW3PFQ5KM7:TR?= MlrnV2FPT0WU
ONS-76 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX3TWM2OD1yLkW4NlQzKM7:TR?= NWnOUYxoW0GQR1XS
KARPAS-299 NUixPJFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwNUi1NFQh|ryP NGL1[2FUSU6JRWK=
DU-4475 NFv1OmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P4[mlEPTB;MD61PFcxOyEQvF2= NWHZNpVEW0GQR1XS
NB69 NWixfmRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrVSWZ[UUN3ME2wMlU6QDJ3IN88US=> MkLhV2FPT0WU
MHH-PREB-1 NVXIblJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jyTWlEPTB;MD62NFcyQSEQvF2= NHLOPW1USU6JRWK=
LU-165 Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\ZSmlEPTB;MD62NVgyOiEQvF2= NFKweFJUSU6JRWK=
LOUCY NX7ufGtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwNkOzOlQh|ryP M2ryPXNCVkeHUh?=
NCI-H526 NXTzeYpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nCTGlEPTB;MD62N|U1OSEQvF2= MVzTRW5ITVJ?
KE-37 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HIU2lEPTB;MD62OFI4PiEQvF2= MojhV2FPT0WU
NALM-6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfFTWM2OD1yLk[0PFYh|ryP MYfTRW5ITVJ?
CW-2 NHvqU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwNkW3PVQh|ryP NHTpW4lUSU6JRWK=
SU-DHL-1 NV3GTZhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwNkW5OFch|ryP NW\ST4dKW0GQR1XS
NB13 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTHTWM2OD1yLk[2PFE4KM7:TR?= M4H0fnNCVkeHUh?=
QIMR-WIL M4DyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zRS2lEPTB;MD62PFM1OyEQvF2= M3j3R3NCVkeHUh?=
ECC12 M1\R[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwN{CwPFYh|ryP NHrKV5hUSU6JRWK=
KALS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;xelAxUUN3ME2wMlcxPDl{IN88US=> MX7TRW5ITVJ?
COR-L279 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXacYNKSzVyPUCuO|A6QTZizszN NI\s[5ZUSU6JRWK=
NB14 MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL2TWM2OD1yLkeyOlE4KM7:TR?= M2P3NHNCVkeHUh?=
CCRF-CEM NX71eIRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7pVmhkUUN3ME2wMlc1PjZzIN88US=> NF;W[41USU6JRWK=
SW954 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwN{W5PVkh|ryP MVfTRW5ITVJ?
IST-SL1 M3X0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwN{ezOFgh|ryP M3fUWXNCVkeHUh?=
LAMA-84 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfOTWM2OD1yLke3OVY4KM7:TR?= MUXTRW5ITVJ?
Daudi NVPMRYtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrmRVl4UUN3ME2wMlc4PjhzIN88US=> MX;TRW5ITVJ?
BC-3 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHJNXJKSzVyPUCuO|g{ODhizszN M3zv[XNCVkeHUh?=
HCC2998 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\UemlEPTB;MD63PFM3KM7:TR?= NUmzdWFIW0GQR1XS
NCI-H69 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO1V3FKSzVyPUCuPFAyPDdizszN NIPjNpJUSU6JRWK=
CPC-N M2TyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnDU2hKSzVyPUCuPFA2OjRizszN MVPTRW5ITVJ?
NOMO-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwOEGwPFQh|ryP NX\KeHlHW0GQR1XS
CESS Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTkTWM2OD1yLkixNVk4KM7:TR?= M3;IfHNCVkeHUh?=
LC4-1 NXjFO4I5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17hTmlEPTB;MD64OFAxPyEQvF2= M3;HfHNCVkeHUh?=
BL-70 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\W[ZRKSzVyPUCuPFU4ODJizszN NEe0[m9USU6JRWK=
ES4 MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDnTWM2OD1yLki1PFY5KM7:TR?= Ml3uV2FPT0WU
HCE-T MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzqZYtKSzVyPUCuPFcyPzFizszN M{D6NHNCVkeHUh?=
JAR MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj1N4FKSzVyPUCuPFc5OjdizszN M{\mW3NCVkeHUh?=
ST486 NHvWPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzkd3doUUN3ME2wMlg4QTF5IN88US=> NUmx[pFpW0GQR1XS
KS-1 NFzXUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO2TmRKSzVyPUCuPFgxQTZizszN MkjXV2FPT0WU
GDM-1 MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHGN5pmUUN3ME2wMlg5Pjh5IN88US=> NI\GbIVUSU6JRWK=
EHEB MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn5cYVKSzVyPUCuPVI2QDVizszN MknlV2FPT0WU
LB2518-MEL M4LmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvDPVd1UUN3ME2wMlk{Ojh2IN88US=> NYrycW4{W0GQR1XS
GOTO MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPjXo0{UUN3ME2wMlk2ODd4IN88US=> MmqyV2FPT0WU
LXF-289 M{XyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M160eGlEPTB;MD65OVkxOSEQvF2= NGjOOoJUSU6JRWK=
ES6 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\0[pRKSzVyPUCuPVY1OzdizszN NXTxenQ2W0GQR1XS
OS-RC-2 NYnQRos6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwOU[4N{DPxE1? NY\veY1VW0GQR1XS
DMS-153 MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\CV2lEPTB;MD65O|Q3QSEQvF2= M4\KVXNCVkeHUh?=
SK-PN-DW NUjDc5Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7xNVdKUUN3ME2wMlk4QDNzIN88US=> NVXZS3hyW0GQR1XS
HH NImwdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvOR|lKSzVyPUCuPVg6PTlizszN MV\TRW5ITVJ?
SH-4 NF21SIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK4S4htUUN3ME2xMlAzPDFizszN NEDjcVlUSU6JRWK=
MOLT-4 M{LUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf0SZRXUUN3ME2xMlA{PDV2IN88US=> MofuV2FPT0WU
TGW MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwMEe2O|Uh|ryP MVTTRW5ITVJ?
L-540 NH36UIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSxTWM2OD1zLkGwOlA1KM7:TR?= NF3RN2JUSU6JRWK=
PF-382 M2O2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknFTWM2OD1zLkGxOVE{KM7:TR?= NELUZ2JUSU6JRWK=
LC-1F Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV24[pd1UUN3ME2xMlEzODB5IN88US=> NWnHfWNLW0GQR1XS
OVCAR-4 M3y4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfVUWpKSzVyPUGuNVMyPjVizszN NHjWW3NUSU6JRWK=
A4-Fuk NXXSZ4FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwMUWzOlQh|ryP MV\TRW5ITVJ?
HCC2218 M2PFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\mN2lEPTB;MT6xOlY1OSEQvF2= M3rUVHNCVkeHUh?=
HAL-01 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwMU[5OFMh|ryP NXzjTWJUW0GQR1XS
IST-MEL1 M2XYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGraSmdKSzVyPUGuNVc3PTlizszN MmnCV2FPT0WU
NCI-H719 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnQTWM2OD1zLkG3PFk5KM7:TR?= MojUV2FPT0WU
EVSA-T NWLLOoZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjrbWJyUUN3ME2xMlE5OTF2IN88US=> MkDQV2FPT0WU
SK-NEP-1 M3TzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHEeYxKSzVyPUGuNlAzPjZizszN MWXTRW5ITVJ?
OCUB-M MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDQWJU5UUN3ME2xMlIyPDh7IN88US=> NGrHR|dUSU6JRWK=
MEG-01 M{fRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\acVJKSzVyPUGuNlIyOThizszN NF\wOpZUSU6JRWK=
no-10 M1jxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H6V2lEPTB;MT6yN|EyOiEQvF2= M{DsTnNCVkeHUh?=
MHH-CALL-2 NVzYUXlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj2e3RqUUN3ME2xMlI1PzJzIN88US=> M3Pw[HNCVkeHUh?=
SK-N-DZ MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe0OZdKSzVyPUGuNlQ4PzZizszN M1LLUHNCVkeHUh?=
SCLC-21H NXjrOFhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXyR3VKSzVyPUGuNlY1PzhizszN NHvKUHBUSU6JRWK=
CTV-1 NXvMTXhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLvTWM2OD1zLkK3OFI2KM7:TR?= NEDj[pFUSU6JRWK=
NB1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjOVFRKSzVyPUGuNlc4OzJizszN M4LkN3NCVkeHUh?=
NCI-H64 M4LGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwMki0OlIh|ryP MULTRW5ITVJ?
MDA-MB-134-VI MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTGTWM2OD1zLkK4OVc4KM7:TR?= NEnsdJdUSU6JRWK=
LB2241-RCC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rTUWlEPTB;MT6yPFY3OyEQvF2= NHTZc5JUSU6JRWK=
8-MG-BA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Xk[mlEPTB;MT6yPFg3PiEQvF2= NGLhPJFUSU6JRWK=
LP-1 NYTRV2ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO3SohKSzVyPUGuNlk6PDdizszN MUTTRW5ITVJ?
LS-411N M1j4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET1bFhKSzVyPUGuN|A6QThizszN NUHQPIpGW0GQR1XS
CAL-148 M4L0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwM{K1OFIh|ryP MXzTRW5ITVJ?
NCI-H2171 NWfzdml6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHxTWM2OD1zLkO0OVAzKM7:TR?= MU\TRW5ITVJ?
JiyoyeP-2003 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILDXodKSzVyPUGuN|U{QSEQvF2= MnLOV2FPT0WU
NCI-H2107 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXaeXZoUUN3ME2xMlM2QDh|IN88US=> NE\vZmpUSU6JRWK=
BB30-HNC NU\iUHhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYThXWZbUUN3ME2xMlM5QTd6IN88US=> NFr6TGpUSU6JRWK=
K-562 NGrIS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwM{myNVkh|ryP NWfnb2FWW0GQR1XS
PSN1 MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnaTWM2OD1zLkSyNlg4KM7:TR?= MnzCV2FPT0WU
HCC2157 NIDVOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTFwNEK2PVEh|ryP MXLTRW5ITVJ?
SBC-1 NGfhW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W1T2lEPTB;MT60Nlc1OSEQvF2= NH7vSnVUSU6JRWK=
MC116 NYHKWnJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrRdG9lUUN3ME2xMlQ{PjF3IN88US=> MUPTRW5ITVJ?
KARPAS-422 NGLxZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fUR2lEPTB;MT60OVM2QCEQvF2= M{e5VHNCVkeHUh?=
LB996-RCC NU\mc5Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PROmlEPTB;MT60O|ExOyEQvF2= MYnTRW5ITVJ?
MSTO-211H MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPNTWM2OD1zLkS3PVg4KM7:TR?= M3THVHNCVkeHUh?=
BT-474 NX;oOllpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT3e3NKSzVyPUGuOVE4PjRizszN M4rTXnNCVkeHUh?=
A388 M{\aTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDHd2l5UUN3ME2xMlUyQTR3IN88US=> NGXYVmFUSU6JRWK=
SJSA-1 NGXIOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jhUGlEPTB;MT61NlI3KM7:TR?= MnPOV2FPT0WU
COLO-829 NX;MNmxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT0TWM2OD1zLkWzOVY1KM7:TR?= MmTUV2FPT0WU
KM-H2 MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF24cIZKSzVyPUGuOVY3PyEQvF2= MUTTRW5ITVJ?
GR-ST M4nZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PZXGlEPTB;MT61OlgzKM7:TR?= M4n1SnNCVkeHUh?=
RPMI-8866 NVnJSIFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PqUmlEPTB;MT62NFE1PCEQvF2= NHPnVpBUSU6JRWK=
KG-1 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O1[WlEPTB;MT62NVkxOSEQvF2= NX;FVnhSW0GQR1XS
NCI-H82 NYT4WHRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rEeGlEPTB;MT62N|QxPiEQvF2= M2rXXHNCVkeHUh?=
LB1047-RCC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zPPGlEPTB;MT62N|Q2QSEQvF2= MX7TRW5ITVJ?
KM12 MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\WZ2lEPTB;MT62OFch|ryP MWTTRW5ITVJ?
NB5 NX73NVR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjOWI5oUUN3ME2xMlY2Pjd5IN88US=> Mkj0V2FPT0WU
HDLM-2 M2LBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DJWWlEPTB;MT62PFI5OSEQvF2= Mk[5V2FPT0WU
KU812 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLTR5lKSzVyPUGuOlk3ODVizszN M{HWS3NCVkeHUh?=
DB NFXOZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXyUWpKSzVyPUGuO|A{PTNizszN MV7TRW5ITVJ?
HD-MY-Z M3f5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjXRpcyUUN3ME2xMlc2OjN2IN88US=> MlP3V2FPT0WU
KURAMOCHI NX3XSHd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLhV2xKSzVyPUGuO|czODdizszN M4HUcXNCVkeHUh?=
ETK-1 NIC5UW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrOOGRSUUN3ME2xMlc5QDd7IN88US=> MmHNV2FPT0WU
SK-UT-1 NHjyPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnvelFtUUN3ME2xMlc6Ozh6IN88US=> NWraTGk3W0GQR1XS
HUTU-80 MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFwN{m1NFgh|ryP M4q5R3NCVkeHUh?=
ES7 NWXPWWVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXjenJKSzVyPUGuPFA{ODJizszN M3vqfHNCVkeHUh?=
SW872 NED0OYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jWeWlEPTB;MT64NVM6PSEQvF2= MoDVV2FPT0WU
TK10 M3O3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\Pc2lEPTB;MT64N|ExQCEQvF2= MWrTRW5ITVJ?
LB831-BLC NID2b2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm5fldIUUN3ME2xMlg{PTZ|IN88US=> NVrsPWJWW0GQR1XS
TE-9 NED0NpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzGOoxKSzVyPUGuPFQ1OjJizszN M2PBNnNCVkeHUh?=
MLMA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLITWM2OD1zLki4NlM1KM7:TR?= NIfL[2hUSU6JRWK=
D-542MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnFT2RKSzVyPUGuPFk{PzNizszN MonTV2FPT0WU
EW-16 NEPSdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{THfGlEPTB;MT65NlczKM7:TR?= M4exbXNCVkeHUh?=
LOXIMVI NGHubIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHi0cm1KSzVyPUGuPVMzQCEQvF2= NIj2fYdUSU6JRWK=
GB-1 NIT3XWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPVUm1KSzVyPUGuPVM5PjZizszN NY\SOFNpW0GQR1XS
IST-SL2 MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ezeGlEPTB;Mj6wNFI3OiEQvF2= NXLSRlAxW0GQR1XS
LAN-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;mUWlEPTB;Mj6wNVk3PiEQvF2= NVL1[nVWW0GQR1XS
NCI-H510A NVjTPHROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLOZ21FUUN3ME2yMlA1PTB{IN88US=> NG[0UodUSU6JRWK=
NCI-H1092 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P3dWlEPTB;Mj6wOVEzPCEQvF2= NHrnU4xUSU6JRWK=
HT MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj6[pZ3UUN3ME2yMlExPDV2IN88US=> MnjkV2FPT0WU
RL95-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPtR2hIUUN3ME2yMlEyPDh{IN88US=> MVjTRW5ITVJ?
NCI-H1355 MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHIb5FuUUN3ME2yMlEyPzl{IN88US=> M2e1N3NCVkeHUh?=
NCI-H720 M1Twbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3WVlNTUUN3ME2yMlE3QDd|IN88US=> NEnCOZhUSU6JRWK=
NCI-H1522 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvN[lFKSzVyPUKuNlE4OjNizszN MWTTRW5ITVJ?
LB373-MEL-D MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;QOHZxUUN3ME2yMlI3QTB{IN88US=> MlzkV2FPT0WU
DG-75 NX;aXVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHBXYVbUUN3ME2yMlI4OTR6IN88US=> NV3JR2Z4W0GQR1XS
ML-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7XTWM2OD1{LkOyPFU2KM7:TR?= NHP5PVdUSU6JRWK=
SF126 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTpeVFKUUN3ME2yMlM{ODl2IN88US=> M2DIdnNCVkeHUh?=
MPP-89 NEPKV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nGPGlEPTB;Mj6zN|E1PSEQvF2= M{W3bHNCVkeHUh?=
NCI-H345 M3XNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLkUXdKSzVyPUKuN|MzPzdizszN M1TBcXNCVkeHUh?=
LS-123 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jqN2lEPTB;Mj6zOFk{PiEQvF2= NF;ZWlRUSU6JRWK=
NB10 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7L[HVKSzVyPUKuOFExQTJizszN M4XGV3NCVkeHUh?=
CGTH-W-1 M1TmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXFfG02UUN3ME2yMlQzOjZ5IN88US=> NUnHcYk{W0GQR1XS
CP66-MEL NF;1NWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XpSWlEPTB;Mj60O|c4KM7:TR?= NUXhT21rW0GQR1XS
L-428 NV7SUpRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTDZW57UUN3ME2yMlQ5PTJzIN88US=> NIS1Z3JUSU6JRWK=
DMS-79 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jlVGlEPTB;Mj61OFExOyEQvF2= NHTtOG1USU6JRWK=
NCI-H1882 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJwNke1OlIh|ryP MmXKV2FPT0WU
KGN MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPU[VMzUUN3ME2yMlc3QDd4IN88US=> NHzieI5USU6JRWK=
EW-1 NGXXW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fHU2lEPTB;Mj63O|A5OyEQvF2= MWfTRW5ITVJ?
U-266 NU\6PIl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLiSYhKSzVyPUKuPFQ5OjNizszN MWPTRW5ITVJ?
COLO-320-HSR M4H4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj5[VFKSzVyPUKuPFU3PDFizszN M2jycHNCVkeHUh?=
KMOE-2 NWfxWlY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJwOEe3NVEh|ryP NYDYUJJUW0GQR1XS
BB49-HNC NHn1Xm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP5TWM2OD1{LkmyOFgh|ryP Mo\NV2FPT0WU
GI-1 M3;qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPYWmZwUUN3ME2yMlkzQTV5IN88US=> NXPTVGFYW0GQR1XS
NCI-H1304 NHHM[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnWTWM2OD1|LkCwOVEyKM7:TR?= NX;IRW9DW0GQR1XS
NCI-H2227 NFvqdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fRbGlEPTB;Mz6wNlA4QSEQvF2= Ml3pV2FPT0WU
U-87-MG MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\lZ|BDUUN3ME2zMlA{PTF|IN88US=> MVPTRW5ITVJ?
NCI-H747 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXhU41KSzVyPUOuNFUzODZizszN M4[0WHNCVkeHUh?=
CTB-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTNwMEWzO|Yh|ryP MUjTRW5ITVJ?
RPMI-8226 MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KzTmlEPTB;Mz6xOFM4QCEQvF2= Mle5V2FPT0WU
NCI-H2141 NHryN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;aXJhwUUN3ME2zMlE3PTZ4IN88US=> MXLTRW5ITVJ?
IST-MES1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrt[|ZKSzVyPUOuNVgzPzlizszN MUjTRW5ITVJ?
TE-5 NUP6TppTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNwMkGzOFIh|ryP M2P3VnNCVkeHUh?=
UACC-257 Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n5dWlEPTB;Mz60N|Y2QSEQvF2= M1;FVHNCVkeHUh?=
SK-N-FI NFHjUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q2O2lEPTB;Mz60OVIzPyEQvF2= NEDPOGxUSU6JRWK=
MFH-ino MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC3TWM2OD1|LkS2OVg6KM7:TR?= NHPOXZlUSU6JRWK=
SF268 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnVOWtlUUN3ME2zMlQ5OTd2IN88US=> MXLTRW5ITVJ?
TE-12 NFvDeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfZeYltUUN3ME2zMlUyPjl7IN88US=> MnzsV2FPT0WU
NB6 MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\kNmlEPTB;Mz61OVU3OyEQvF2= NVfySYVMW0GQR1XS
DJM-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnwXJFKSzVyPUOuOVk5QTlizszN MkPzV2FPT0WU
MZ1-PC MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTNwNkG2NlQh|ryP NFXXRW5USU6JRWK=
OCI-AML2 NWDsS4xNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnlc5lKSzVyPUOuOlI3PzFizszN NHvWeVBUSU6JRWK=
NCI-H1155 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrpUWR{UUN3ME2zMlcxQTR5IN88US=> M1XlTXNCVkeHUh?=
RKO Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXNdYhsUUN3ME2zMlc4OTh7IN88US=> M2OwdnNCVkeHUh?=
ECC4 NYjaSoxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDJdmk5UUN3ME2zMlk4OTl3IN88US=> M4XqPXNCVkeHUh?=
BB65-RCC MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvETWM2OD1|Lkm3OVQ4KM7:TR?= MoHBV2FPT0WU
EB-3 NInCeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;XTWM2OD1|Lkm5OlM{KM7:TR?= MoXQV2FPT0WU
SHP-77 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPxSGpKSzVyPUSuNFA2OjRizszN NV;4XmxWW0GQR1XS
NCI-H2196 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3xTWM2OD12LkC1OlI2KM7:TR?= MlK3V2FPT0WU
GI-ME-N NYTnSo53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq0[pZVUUN3ME20MlA3Ozl7IN88US=> NWm3XIxXW0GQR1XS
MN-60 NHLKVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\TPWcxUUN3ME20MlExQDdizszN MWPTRW5ITVJ?
NCI-H1694 NH;5b2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTRwMUO0NFUh|ryP NGjrU4pUSU6JRWK=
LU-65 NH3rU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLlTWM2OD12LkG1N|MzKM7:TR?= Ml7yV2FPT0WU
NCI-H1436 NGfoO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfNTWM2OD12LkG4N|M{KM7:TR?= MXrTRW5ITVJ?
KINGS-1 MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHF[ZdtUUN3ME20MlMyPDN{IN88US=> MUDTRW5ITVJ?
GT3TKB MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfDTWM2OD12LkOzNlY5KM7:TR?= M3rERnNCVkeHUh?=
Becker MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\0e2NKSzVyPUSuN|c{OTJizszN MUnTRW5ITVJ?
HCC1187 M4DNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTRwOEm2OVch|ryP M3radHNCVkeHUh?=
D-502MG MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjFTWM2OD13LkCwOFE3KM7:TR?= MnnUV2FPT0WU
VA-ES-BJ NFvtPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTVwMUO3O|gh|ryP M33qSXNCVkeHUh?=
NB7 M2n1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWwWJVIUUN3ME21MlE1OTF{IN88US=> NU\SenJYW0GQR1XS
SW962 NGjKdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTVwM{i4NVQh|ryP M2fsfnNCVkeHUh?=
no-11 NGfyTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvtSHdKSzVyPUWuO|Y{PDNizszN M{C2TnNCVkeHUh?=
KNS-81-FD NX3CeoxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfiTWM2OD13LkmwOlk1KM7:TR?= NV[3WYpyW0GQR1XS
COLO-684 NX;YN493T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq5TWM2OD13Lkm5OFk1KM7:TR?= M4fGenNCVkeHUh?=
D-263MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr2cHNKSzVyPU[uNFg5QTVizszN M4HzXnNCVkeHUh?=
EW-24 NX7QNYZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULYOJFLUUN3ME22MlI5PTFizszN MlW0V2FPT0WU
TE-10 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTZwNEK2NlMh|ryP M{izTXNCVkeHUh?=
EKVX M4K0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTZwNE[zNlEh|ryP MkDQV2FPT0WU
NCI-H1648 NHTDdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTZwNke1OVch|ryP M4LUR3NCVkeHUh?=
LB771-HNC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTlTWM2OD14LkmyN|AyKM7:TR?= MlOxV2FPT0WU
SK-MEL-1 NHn2VXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRThwMUOxOlYh|ryP MXLTRW5ITVJ?
COLO-668 NFHzbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnuOoFKSzVyPUiuNlc4QDZizszN M{\mN3NCVkeHUh?=
EW-12 NVywelhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRThwNEC4NFMh|ryP M2fqS3NCVkeHUh?=
A253 NFTJTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rrSmlEPTB;OD64OFY3OSEQvF2= M1jGdXNCVkeHUh?=
NCI-H2126 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjlTWM2OD16Lki5N|E6KM7:TR?= NEfFUHZUSU6JRWK=
Calu-6 M3jwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRThwOUmwOFIh|ryP NW\FdZhCW0GQR1XS
NCI-H23 NFGzXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe2U2FKSzVyPUmuNVc4PDZizszN M1fHUXNCVkeHUh?=
WSU-NHL NH;sSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPRcFRwUUN3ME25Mlc4PDd6IN88US=> M3nPSXNCVkeHUh?=
MMAC-SF M1\ubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjBTWM2OD17Lkm3PVA1KM7:TR?= MXzTRW5ITVJ?
SK-LMS-1 M{mwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFyLkK4N|Qh|ryP M3;V[nNCVkeHUh?=
GCIY MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S3NGlEPTB;MUCuOVkzPCEQvF2= NUG0VGVMW0GQR1XS
TE-15 M2ruU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHPTWM2OD1zMT62NFA1KM7:TR?= MnvOV2FPT0WU
EoL-1-cell M1q1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELhe2lKSzVyPUGxMlc3QDJizszN NEjEUGZUSU6JRWK=
NCI-H2081 MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFzLke3PFYh|ryP MUfTRW5ITVJ?
EW-3 NIX1eoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnQTWM2OD1zMj6yOFY{KM7:TR?= M3n3SnNCVkeHUh?=
CAS-1 NFvKfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF{LkO2N|Eh|ryP Mn3XV2FPT0WU
C2BBe1 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfxTWM2OD1zMj62NVMyKM7:TR?= M4jWWnNCVkeHUh?=
D-247MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTUTWM2OD1zMj63PVUzKM7:TR?= NHn0OJJUSU6JRWK=
NCI-SNU-5 NEXJXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL5VpNKSzVyPUGyMlgxOTNizszN NWfTbVB1W0GQR1XS
LS-1034 NU\pPZNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WyO2lEPTB;MUSuN|k4PSEQvF2= MorDV2FPT0WU
EW-18 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXQVGVKUUN3ME2xOE41PDhizszN NFv3[FNUSU6JRWK=
Raji MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjyTWM2OD1zND61NFQ6KM7:TR?= NF7OV25USU6JRWK=
D-283MED M{HQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILnTFhKSzVyPUG0MlYzPzFizszN MoLoV2FPT0WU
MZ2-MEL MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XOWmlEPTB;MUSuPVY6PiEQvF2= MV\TRW5ITVJ?
NCI-SNU-16 NF;RRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m3OWlEPTB;MUWuOFY{OyEQvF2= MWDTRW5ITVJ?
P30-OHK MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDuWVdKSzVyPUG3Mlc5OzFizszN Mn:4V2FPT0WU
RXF393 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2OxVmlEPTB;MUmuNFE5PiEQvF2= MULTRW5ITVJ?
NCI-H1395 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnKxTWM2OD1{MD62O|A{KM7:TR?= MV\TRW5ITVJ?
U-698-M NIP0e|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfZXXhKSzVyPUKwMlcxPzVizszN NYSwW3hpW0GQR1XS
NCI-SNU-1 NEPPXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJyLkeyNlMh|ryP NGDUOJZUSU6JRWK=
SW684 M4\ncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGwS3BKSzVyPUKxMlE4OTZizszN M17JTnNCVkeHUh?=
NCI-H716 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[1TGlEPTB;MkGuN|E2PCEQvF2= MnPzV2FPT0WU
JVM-2 NIPhWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzCOZVsUUN3ME2yNU41OTN|IN88US=> NHL0VY1USU6JRWK=
NCI-H1581 M2HmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXDVHFKSzVyPUKyMlQyPDhizszN NFjhdI5USU6JRWK=
CA46 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G2XWlEPTB;M{GuOlk{PiEQvF2= NFXKeXJUSU6JRWK=
SNB75 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXPTWM2OD1|Mz62OVA{KM7:TR?= NYi5S4w2W0GQR1XS
KNS-42 NITxVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTN3Lkm2NlQh|ryP M33PdnNCVkeHUh?=
TUR Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTN4LkC1NlEh|ryP MW\TRW5ITVJ?
REH NX7TPXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTN5LkiyNVEh|ryP MWXTRW5ITVJ?
EW-22 M2Lw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR{LkK4PFUh|ryP MkPJV2FPT0WU
NCI-H446 NEDGPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf0cm1KSzVyPUSyMlc5PTNizszN NVH3dmV3W0GQR1XS
ES3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvMTWM2OD12Mz6xN|M6KM7:TR?= NFjEdY5USU6JRWK=
EW-11 NWTlOGF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qxcmlEPTB;NESuPFIyQCEQvF2= MoDiV2FPT0WU
RH-1 NGLvN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[0b2lEPTB;NEeuOVgyOiEQvF2= NGrZVoNUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

- Collapse

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

- Collapse
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275
Smiles NC1=CC=CC=C1NC(=O)C2=CC=C(CNC(=O)OCC3=CN=CC=C3)C=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03829930 Recruiting Drug: Entinostat|Drug: Enzalutamide Prostate Adenocarcinoma George Washington University May 1 2019 Phase 1
NCT03765229 Recruiting Drug: Entinostat|Drug: Pembrolizumab Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 22 2019 Phase 2
NCT03473639 Recruiting Drug: Entinostat|Drug: Capecitabine Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals January 29 2019 Phase 1
NCT03361800 Active not recruiting Drug: Entinostat Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) November 28 2018 Early Phase 1
NCT03192111 Completed Drug: Entinostat Renal Impairment|Healthy Volunteer Syndax Pharmaceuticals July 27 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID